Biodesix Inc (BDSX) Stock Price, Quote & News

Company Profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 303 417 0500

Fax: 866 432 3338

Website: www.biodesix.com

Address:

919 West Dillon Road, Louisville, United States

_SquidGains_ Nov. 13 at 11:36 PM

$CLSD $BDSX $STKH $GP.X ,

0 · Reply

_ReddBullyz Nov. 12 at 4:13 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $CLSD $BDSX $STKH $GP.X Track,

0 · Reply

MoneyGroupLLC Nov. 12 at 5:11 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.07 Profit : +44% (Turn every $1 into $1.44) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

PiratesKingLuffy Nov. 12 at 3:09 AM

AMZE Expecting a big move here tomorrow. Very bullish close today!! AMZE has extended its partnership with Adobe Express, expanding platform access to creators in India — a market with over 2 million monetized creators and $350B in consumer spending. The integration lets users design and sell custom merchandise directly on Amaze, streamlining the path from creation to commerce. The expansion follows Amaze’s showcase at Adobe MAX 2025. Lets bank on AMZE such a gem here! $CRE $BDSX $IPST $AREB .,

0 · Reply

MoneyGroupLLC Nov. 11 at 5:30 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.08 Profit : +69% (Turn every $1 into $1.69) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Nov. 10 at 4:53 PM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.09 Profit : +78% (Turn every $1 into $1.78) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Nov. 9 at 4:48 AM

0 · Reply

MoneyGroupLLC Nov. 8 at 5:37 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.08 Profit : +54% (Turn every $1 into $1.54) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Nov. 7 at 4:11 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.09 Profit : +83% (Turn every $1 into $1.83) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Nov. 6 at 4:08 PM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.08 Profit : +68% (Turn every $1 into $1.68) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:01 PM EST - 11 days ago

Biodesix Announces Third Quarter 2025 Results and Highlights

Oct 30, 2025, 6:17 AM EDT - 15 days ago

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

Oct 22, 2025, 6:17 AM EDT - 23 days ago

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

Oct 20, 2025, 6:00 AM EDT - 25 days ago

Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 15, 2025, 6:09 AM EDT - 4 weeks ago

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

Oct 6, 2025, 10:13 AM EDT - 5 weeks ago

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Sep 11, 2025, 8:00 AM EDT - 2 months ago

Biodesix Announces One-for-Twenty Reverse Stock Split

Sep 5, 2025, 6:00 AM EDT - 2 months ago

Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference

Aug 19, 2025, 9:47 AM EDT - 3 months ago

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

Aug 9, 2025, 11:07 AM EDT - 3 months ago

Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:06 PM EDT - 3 months ago

Biodesix Announces Second Quarter 2025 Results and Highlights

Aug 5, 2025, 6:00 AM EDT - 3 months ago

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 6:00 AM EDT - 4 months ago

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 10, 2025, 6:17 AM EDT - 5 months ago

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

May 22, 2025, 5:03 PM EDT - 6 months ago

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

May 21, 2025, 6:00 AM EDT - 6 months ago

Biodesix to Participate in Upcoming Investor Conferences

May 15, 2025, 6:00 AM EDT - 6 months ago

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

May 14, 2025, 4:01 PM EDT - 6 months ago

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

May 13, 2025, 8:22 PM EDT - 6 months ago

Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 6 months ago

Biodesix Announces First Quarter 2025 Results and Highlights

Apr 29, 2025, 6:00 AM EDT - 7 months ago

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 23, 2025, 6:00 AM EDT - 7 months ago

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Mar 3, 2025, 8:06 PM EST - 9 months ago

Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:01 PM EST - 9 months ago

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Feb 26, 2025, 6:00 AM EST - 9 months ago

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 6:00 AM EST - 9 months ago

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Jan 10, 2025, 6:00 AM EST - 11 months ago

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Jan 7, 2025, 6:00 AM EST - 11 months ago

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Nov 1, 2024, 3:29 PM EDT - 1 year ago

Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 6:00 AM EDT - 1 year ago

Biodesix Announces Third Quarter 2024 Results and Highlights

Oct 29, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Participate in Three Investor Conferences in November

Oct 18, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Oct 7, 2024, 6:00 AM EDT - 1 year ago

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Present at Two Investor Conferences in September

Aug 7, 2024, 8:52 PM EDT - 1 year ago

Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Biodesix Announces Second Quarter 2024 Results and Highlights

Aug 6, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Present at Canaccord Genuity's 44th Annual Growth Conference

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

Jun 18, 2024, 8:13 AM EDT - 1 year ago

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”

May 28, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Participate in Two Investor Conferences in June

May 21, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting

May 10, 2024, 1:06 AM EDT - 1 year ago

Biodesix, Inc. (BDSX) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 1 year ago

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

May 7, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference

Apr 24, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 9, 2024, 5:00 PM EDT - 1 year ago

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Apr 5, 2024, 7:17 AM EDT - 1 year ago

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

Mar 25, 2024, 6:00 AM EDT - 1 year ago

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Mar 1, 2024, 12:35 PM EST - 1 year ago

Biodesix, Inc. (BDSX) Q4 2023 Earnings Call Transcript

_SquidGains_ Nov. 13 at 11:36 PM

$CLSD $BDSX $STKH $GP.X ,

0 · Reply

_ReddBullyz Nov. 12 at 4:13 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $CLSD $BDSX $STKH $GP.X Track,

0 · Reply

MoneyGroupLLC Nov. 12 at 5:11 AM

0 · Reply

PiratesKingLuffy Nov. 12 at 3:09 AM

0 · Reply

MoneyGroupLLC Nov. 11 at 5:30 AM

0 · Reply

MoneyGroupLLC Nov. 10 at 4:53 PM

0 · Reply

MoneyGroupLLC Nov. 9 at 4:48 AM

0 · Reply

MoneyGroupLLC Nov. 8 at 5:37 AM

0 · Reply

MoneyGroupLLC Nov. 7 at 4:11 AM

0 · Reply

MoneyGroupLLC Nov. 6 at 4:08 PM

0 · Reply

Vandenberg23 Nov. 6 at 12:58 PM

$BDSX Were we not told this company would be EBITA positive in 2025?

0 · Reply

GTMStox Nov. 6 at 1:07 AM

$BDSX Feeling like a lifeline of cash will be coming their way soon. Will be easy double from these levels. I would advise against being short.

1 · Reply

GTMStox Nov. 6 at 1:04 AM

$BDSX

0 · Reply

healthcareguru Nov. 5 at 8:23 PM

$BDSX are you guys effing stupid?!? They’re out of cash and bankrupt in 4mos without another major raise… Back to <$5. 🤦‍♂️👎 $XLV $IWM $XBI

1 · Reply

MoneyGroupLLC Nov. 5 at 2:26 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.07 Profit : +47% (Turn every $1 into $1.47) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

GTMStox Nov. 4 at 1:19 PM

$BDSX This is way undervalued

0 · Reply

PaulWillRoss Nov. 4 at 11:26 AM

$BDSX Why can't this stock get out of its own way ? With news like that we should be up 25%+ pre market. Nothin.

0 · Reply

MoneyGroupLLC Nov. 4 at 4:28 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.10 Profit : +94% (Turn every $1 into $1.94) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

d_risk Nov. 3 at 11:48 PM

$BDSX - Biodesix Inc. Common Stock - 10Q - Updated Risk Factors BDSX flags risks from possible federal shutdowns disrupting healthcare funding, Nasdaq listing compliance and delisting threats, new and uncertain U.S. trade tariffs, and major FDA regulatory shifts for lab-developed tests—including vacated rules, potential new laws, and looming compliance deadlines that could raise costs and hinder growth. #Healthcare #FederalFunding #StockMarket #TradeTariffs #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/BDSX/10-Q/2025-11-03

0 · Reply

Wisenheimer Nov. 3 at 11:16 PM

$BDSX 8m qtrly burn - 16mm in cash / keep that atm humming - buyers beware

0 · Reply

topstockalerts Nov. 3 at 10:59 PM

After Hours Top Gainers PT2 $SANM $BDSX $PBM $EXAS $TLIH

0 · Reply

MoneyGroupLLC Nov. 3 at 1:52 AM

Enter: $BDSX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.05 - $0.05 Sell Price: $0.11 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Market Cap	62.85M
Revenue (ttm)	71.32M
Net Income (ttm)	-42.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60.19%
Debt to Equity Ratio	-27.40

Volume	81,000
Avg Vol	190,585
Day's Range	N/A - N/A
Shares Out	7.96M
Stochastic %K	67%
Beta	0.98
Analysts	Strong Sell
Price Target	$33.33